RVMD as reported
Revolution Medicines, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied
- Net Income
- −$1.77B
Net Income · +118% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$1.23B
Free Cash Flow · +76% year on year · trailing twelve months to Q2 2026
- EPS
- −$8.85
EPS · +96% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2024 · 6 quarters behind |
| Net Income | −$1.77B | +118% | Q2 2026 |
| EPS | −$8.85 | +96% | Q2 2026 |
| Op Margin | −1650% | n/a | Q2 2023 · 12 quarters behind |
| Net Margin | −1524% | n/a | Q2 2023 · 12 quarters behind |
| ROE | −72% | n/a | Q2 2026 |
| ROA | −48% | n/a | Q2 2026 |
| Free Cash Flow | −$1.23B | +76% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Revolution Medicines, Inc. (RVMD) - Revenue & ProfitRevenue & ProfitRevolution Medicines, Inc. (RVMD)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com